Welcome to the Vergecast, the flagship podcast of number go up and also down. I'm your friend David Pierce and I am sitting in my backyard on sprinkler duty. So, a thing you've probably already guessed about me given my entire deal is that I'm not good at keeping plants alive.Um, I can't remember how tall the grass is supposed to be when you mow it. I don't exactly know which of my plants is which and how often I'm supposed to water any of them. But we had some work done on the backyard this weekend.They th ...

Product & Technology - Signos leverages AI and continuous glucose monitoring (CGM) via a wearable biosensor to provide real-time metabolic insights for weight management [2][3] - The device, featuring a micro-needle, is worn for 15 days and provides data accessible via a phone app [3][4] - Signos aims to predict weight-related outcomes by providing personalized recommendations (e.g, suggesting a walk after a meal) based on glucose levels [5] - Signos integrates with other wearable devices like Apple Watch, complementing their data with AI-driven predictions [13][14] Market & Competition - Signos positions itself as a complementary solution to GLP-1 drugs, targeting a broader audience beyond those with obesity, focusing on weight loss and maintenance [7] - The company aims to establish metabolism as the "fifth vital sign," promoting continuous monitoring outside of clinical settings [8] - The FDA clearance covers the device's accuracy in measuring glucose levels for weight management, including weight loss and maintenance [9] Business Model & Financials - The service costs $129 per month and is FSA/HSA eligible [6] - Signos is actively pursuing partnerships with insurers for reimbursement coverage [6] Clinical Benefits - Stabilizing glucose levels can lead to improved sleep quality, as demonstrated by a user experience of tripled deep sleep duration [11][12]